Syngulon

Rue Du Bois Saint Jean 15/1

4102 Seraing

BE

Syngulon

Foundation date

7-03-2013

Sector

#Biotechnology - other

Subsector

Syngulon is developing original genetic technologies to improve the efficiency of microorganisms.Syngulon has introduced a new genetic technology (US Patent 9,333,227, issued on May 10, 2016) for the use of bacteriocin/immunity in any bacteria, yeast or algae for controlled growth of microorganisms.This issued patent is part of a new worldwide patent portfolio developed by Syngulon and available for licensing in all fields of use on a non-exclusive basis.  

Latest news

  • Mayne Pharma and Mithra announce TGA approval of Nextstellis® oral contraceptive

    22 hours ago

  • Bone Therapeutics and Link Health sign a non-binding term sheet for the global rights of ALLOB

    22 hours ago

  • S-Biomedic announces topline results of a successful clinical study in acne

    Friday November 26th 2021